IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung CancerPR Newswire • 2 days ago
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer IDEAYA Biosciences Announces Selection of...
Share to Feed
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN...
IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
IDEAYA Biosciences, Inc. (NASDAQ:IDYA Get Free Report) has been given an average recommendation of Buy by the thirteen analysts that are presently covering the firm...
This price move could indicate a change in the trend, and may be a sell signal for investors...
IDEAYA Biosciences (NASDAQ:IDYA Free Report) had its target price hoisted by Citigroup from $40.00 to $60.00 in a report released on Thursday morning, Benzinga reports. The brokerage...
IDEAYA Biosciences, Inc. (NASDAQ:IDYA Get Free Report) rose 3.3% during trading on Tuesday . The company traded as high as $45.02 and last traded at $45.02. Approximately 44,215 shares...
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA (pembrolizumab) in Patients with Endometrial Cancer IDEAYA Announces Clinical Collaboration to Evaluate IDE161...
Latest Ratings for IDYA
DateFirmActionFromTo Mar 2022StifelUpgradesHoldBuy Sep 2021StifelInitiates Coverage OnHold Aug 2021HC Wainwright & Co.MaintainsBuy
View More Analyst Ratings for IDYA...